



**Saving lives of
children with cancer
through excellence
in research, medical
care, and education.**

This page is intentionally left blank

.....

CONTENT PAGE

Topic:	Page
About VIVA	1
Message from the Chairman	3
VIVA's Projects:	
VIVA-NUS Childhood Cancer Programme	4
VIVA-University Children Cancer's Centre (vuc ³)	4
VIVA-Goh Foundation Professorship in Paediatric Oncology	4
Mrs. Lee Kong Chian Chair in Advanced Cellular Therapy	5
VIVA-NUS Centre of Translational Research in Acute Leukaemia (CENTRAL)	6
VIVA-KKH Paediatric Brain and Solid Tumour Programme	7
Sharing Knowledge:	8
Continuing education for medical professionals:	9
VIVA Education webinars	
Life Programme & Fundraising:	
VIVA Activities	18
VIVA Fundraising	22
Award:	
Business China Award 2021	26
Efforts against the Coronavirus:	
VIVA against COVID	27
VIVA in the Press:	28
Finance Matters:	
Financial Statements	29
VIVA's Internal Code and Key Members:	
Code of Governance	39
Board of Directors	41
External Advisory Board	43
Thank You	45

ABOUT VIVA

The VIVA Foundation for Children with Cancer was incorporated in Singapore on 6 February 2006 as a Public Company Limited by Guarantee. It was registered under the Charities Act on 25 April 2006, with Institution of Public Character (IPC) status.

UEN:	200601578E
Charity Registration No.:	01961
IPC Effective Period:	15 May 2021 – 14 May 2024
HEF Registration Number:	HEF 0105/G
Registered Address:	8 Sinaran Drive #03-01 Novena Specialist Center Singapore 307470
Chairman:	Mrs Jennifer Yeo (Mdm Leong Lai Peng)
Auditors:	Assurance Partners LLP
Bankers:	Citibank Singapore Ltd DBS Bank Ltd Oversea-Chinese Banking Corporation Ltd United Overseas Bank Ltd

FUNDING SOURCES

VIVA Foundation is financially supported by donations from members, donors and government grants.

VOLUNTEERING

VIVA Foundation is open to the public for participation in its charitable activities in aid of children with cancer.

STAFFING

As at 31 December 2021, there are eight (8) full-time staff employed by VIVA Foundation.



OBJECTIVES

To improve the cure of children with cancer and to help survivors thrive, so that they can live long, healthy, happy and meaningful lives through:



Partnering and funding scientists and doctors in key projects and clinical research



Supporting institutions to provide optimum facilities and level of care



Empowering doctors, nurses, and care-providers, patients and survivors through training and knowledge-sharing

MESSAGE FROM THE CHAIRMAN



2021 proved to be an eventful year for VIVA as many milestones were reached.

Our 15th St Jude-VIVA annual forum in paediatric oncology was conducted virtually for the first time in our history. We had 4,015 registrants comprising scientists, doctors, nurses and allied health professionals from 32 different countries. In collaboration with VIVA China Children's Cancer Foundation a charity from Hong Kong, we also featured the doctors leading the largest study group in the world with 15000 children with Acute Lymphoblastic Leukemia being treated at 25 hospitals in China and Hong Kong, who presented their findings at our Forum. Another first was the debut of the Rare Tumour Board in collaboration with Dr Godfrey Chan of Hong Kong University and Survivorship in collaboration with Dr Melissa Hudson of St Jude Children's Research Hospital.

VIVA also organized the first virtual Hero Challenge which attracted registrations of almost 3000 runners. Our VIVA ambassador, Kishore

Mahubani ran 70 km in 10 days.

We had our first food festival wholly sponsored by Ang Kiam Meng of Jumbo Seafood to help VIVA raise funds to support children with cancer and our donors enjoyed the delicious food and excellent service of Jumbo Seafood whether they dined in at home or dined out at the Jumbo Seafood restaurants.

We presented our very first Art Exhibition in collaboration with Aspiration Fine Arts Society (Aspiration) championed by our director Mrs Cynthia Lee. The Principal Mr. Lin Luzai and his students who are members of Aspiration enthusiastically donated their art works to raise funds for VIVA and also mobilized their families and friends to support VIVA.

VIVA also started our Food Sharing Programme. Our partners in good works, Hemispheres Foundation and Mr Andre Lim ensured that organic vegetable and canned food, vitamins and fruits respectively were supplied to the VIVA children periodically.

Our weekly storytelling series was launched in both English and Chinese. The storytellers in Mandarin were kindly sponsored by Hooks on Books while the storytellers in English were from all walks of life and included celebrities Selena Tan from Dim Sum Dollies and Anne Mahubani.

To give thanks for all the blessings in life, VIVA presented free online Thanksgiving and Christmas concerts. We thank all performers including VIVA directors KK Chua and YY Yoon, who gave amazing performances.

Although 2021 has been a trying period for everyone with the Covid-19 pandemic and its restrictions, there was no lack of goodwill and love. A big Thank You to our donors, volunteers and supporters who have supported VIVA to advance our mission to help the children with cancer to live longer, healthier and happier lives. We look forward to your continuing support so that we are able to help even more children with cancer not just to survive, but to thrive.

A handwritten signature in black ink that reads "Jennifer Yeo". The signature is written in a cursive, flowing style.

Mrs Jennifer Yeo
Executive Chairman (Pro bono) and Founder
VIVA Foundation for Children with Cancer

VIVA-NUS CHILDHOOD CANCER PROGRAMME

VIVA-UNIVERSITY CHILDREN CANCER'S CENTRE (VUC³)

The VIVA-University Children's Cancer Centre (VIJC³) is VIVA's first childhood cancer centre of excellence. The VUC³ provides a comprehensive childhood cancer treatment programme with capabilities of advanced cellular therapies and right siting of care with a 16-bed Day Therapy Centre for chemotherapy. It is housed at the National University Hospital (NUH).

VIJC³ was built in 2008 and funded by VIVA through its donors, such as the Lee Foundation and Tote Board.

Together with the Goh Foundation and Children's Cancer Foundation translational clinical research funding, VUC³ has the capability to handle increasingly complex cases of childhood cancer from both Singapore and the surrounding region.

In 2021, the VUC³ continued its mission to provide excellent medical care for children with cancer, with 270 inpatient admissions and 4,933 outpatient therapies. Specialists at the VIJC³ also conducted 6 CAR-T infusions and 1 bone marrow transplants over the course of the year.

MEDICAL CARE (2021)

270

Inpatient admissions

4,933

Outpatient therapies

1

Bone marrow transplants

6

CAR T-Cell Therapy

VIVA-GOH FOUNDATION PROFESSORSHIP IN PAEDIATRIC ONCOLOGY



A/P Allen Yeoh

In 2012, Associate Professor Allen Yeoh was appointed the VIVA-Goh Foundation Associate Professor in Paediatric Oncology in National University of Singapore. The VIVA-Goh Professorship was created to advance childhood cancer care in Singapore and Asia.

Over the years, A/Prof Yeoh has successfully conducted 3 successful generations of Malaysia-Singapore ALL studies. Malaysia-Singapore ALL study helped raised the cure rate of ALL from 55% in Malaysia and 75% in Singapore to 85% currently. The treatment is now extended to young adult with ALL. Together with Prof Dario Campana, the Mrs Lee Kong Chian Chair funded by VIVA Foundation, A/Prof Yeoh successfully started 2 innovative cell-based therapy for acute lymphoblastic leukaemia in Singapore.

In addition, A/Prof Yeoh is helping with education outreach to help improve the care of ALL in the region.

International Academic
Community Service

MRS LEE KONG CHIAN CHAIR IN ADVANCED CELLULAR THERAPY



Dr. Dario Campana

VIVA began the Mrs Lee Kong Chian Chair in Advanced Cellular Therapy with the support of the Lee Foundation, which supports renowned experts Dario Campana and his team at the National University of Singapore to conduct research on cell-based therapy and clinical trials for breakthroughs in cancer treatment.

One such treatment is the experimental CAR-T cellular immunotherapy which was developed by the Chair Professor Campana, who won the 2020 President's Technology Award for his work in using immune cells for the treatment for cancer.

The clinical results work in using CAR-T cells in the treatment of both children and adults are highly encouraging. These results promise to usher in a new era in ALL treatment.

The work done under Mrs Lee Kong Chian Chair has also since unlocked over \$6M of additional research funding from NCIS Cancer Centre, the Goh Foundation, the Lee Foundation, and the Children's Cancer Foundation, amongst others. To this end, Dr Campana recently obtained his 3rd consecutive Singapore Translational Research (STaR) Investigator Award offered by the Ministry of Health's National Medical Research Council to support his research. These additional funding ensures that we can all continue the development of new cures that can save the lives of children with cancer.

VIVA is grateful for this ongoing collaboration which has been ongoing since the Chair's inception in 2013 and would also like to thank all our donors for their contributions to this programme.

Total funds raised for VIVA-University Children's Cancer Centre,
Mrs Lee Kong Chian Chair, VIVA-Goh Foundation Professorship and
VIVA Education and Research Fund.

\$56,068,751*

* This figure includes funds raised by: VIVA
and our respective partners



VIVA-NUS CENTRE OF TRANSLATIONAL RESEARCH IN ACUTE LEUKAEMIA (CentRAL)

From left: Mrs Jennifer Yeo, Prof. Tan Chorh Chuan, Mr Ho Cheng Huat

ACCREDITATION

- ✓ Laboratory tests accredited by the Singapore Accreditation Council as fulfilling base requirements for ISO 15189
- ✓ First university-based laboratory in Singapore to receive SingClass accredited laboratory mark

TOTAL FUNDS RAISED FOR THIS PROGRAMME IN 2021

\$ 1,300,000

TOTAL FUNDS RAISED FOR THIS PROGRAMME

\$ 8,026,692*

* This figure includes funds raised by: VIVA and our respective partners

In 2014, VIVA set up the **VIVA-NUS Centre for Translational Research in Acute Leukaemia (CentRAL)** in collaboration with the National University of Singapore. CentRAL was established to aim to further research on paediatric acute leukaemia, the most common form of childhood cancers. Ultimately, it serves to improve cure rates of children and adults with acute lymphoblastic leukaemia (ALL).

The facility is led by VIVA-Goh Foundation Assoc Prof Allen Yeoh and Mrs Lee Kong Chian Chair Prof Dario Campana from the NUS School of Medicine.

Since its inception, CentRAL was able to conduct over 2,500 molecular tests for childhood cancer patients. The tests enabled doctors to better determine the best levels of treatment, with 85% of patients receiving less chemotherapy, less side effects, improving their chances for cure.

CentRAL was also awarded the Singapore Accreditation Council SINGCLASS Accredited

Laboratory Mark—the first university-based laboratory in Singapore to do so—enhancing its credibility and assuring the public that services are conducted in line with globally-recognised standards. Aside from this, six laboratory tests developed by CentRAL were also accredited by the SAC as fulfilling ISO 15189 requirements.

Since VIVA's establishment in 2006, we have been supporting the Malaysia-Singapore Acute Lymphoblastic Leukaemia (ALL) Study. CentRAL's molecular testing in children with ALL is the world's first clinical trial incorporating the IKZF1 gene risk assignment as identified from the study. This has resulted in an improvement in cure rates and delivered one of the best ALL treatment outcomes in the world—a drop in relapse rates from 30.4% to 13.5%. CentRAL will continue this study, after successfully clinching additional funding from the highly competitive National Medical Research Council grant.

VIVA-KKH PAEDIATRIC BRAIN AND SOLID TUMOUR PROGRAMME

Despite advances in the treatment of paediatric cancers, outcomes for most childhood solid tumours remain inferior to blood cancers.

Established in 2015, the VIVAKKH Paediatric Brain and Solid Tumour Programme is a collaborative clinical and research partnership between VIVA, KK Women's and Children's Hospital (KKH), and St. Jude Children's Research Hospital to seek advancements in childhood brain and solid tumours by improving clinical care, translational research, education, and leveraging the expertise and strength of partner institutions.

Even though the pilot programme ended in 2018, the advancements made during the collaboration continues to benefit a wider public. New diagnostic tests were developed and rolled out across Singapore and the region. Patients received improved medical care through a multi-disciplinary brain tumour clinic providing a one-stop outpatient services,

which continues to run today.

Up to end 2021, net research output of the Programme has amounted to 81 publications in peer-reviewed journals and 71 presentations. 25 competitive grants totalling \$4.7 million were brought in to supplement the funding from the Programme.

Patients now have more access to several international multicentre paediatric solid tumour clinical trials that have opened at KK Women's and Children's Hospital.

6 doctors from regional low- and middle-income countries benefited from the exchange programme. These included 4 observerships in paediatric pathology and 2 fellowships in paediatric surgical oncology, training alongside the SingHealth clinical team and engaging in research and education projects.

MEDICAL CARE AND ACHIEVEMENTS

\$4.7m Grants

71 Presentations

81 Publications

TOTAL FUNDS RAISED FOR THIS PROGRAMME

\$ 26,208,937*

**This figure includes the seed funding \$8,200,000 raised by VIVA and additional funds from partners and government matching.*



Steering committee members of the programme

CONTINUING EDUCATION FOR MEDICAL PROFESSIONALS: VIVA EDUCATION WEBINARS



VIVA 2021 EDUCATION WEBINARS IN NUMBERS

900+ Participants

36 Countries

9 Webinars

In the wake of the COVID-19 pandemic, VIVA's annual 14th St.Jude- VIVA Forum on Paediatric Oncology was cancelled in the interest of safety for all medical professionals attending, staff, and patients.

However, as part of VIVA's mission to ensure that medical education continues even though the pandemic has made face-to-face learning sessions impossible, we began to organise VIVA Education Webinars in partnership with the medical community, and supporters such as Bayer and Amgen.

VIVA EDUCATION WEBINARS



Speaker

Dr Sharon Plon, Baylor College of Medicine, USA

Panelist

Dr Joanne Ngeow, National Cancer Centre, Singapore

Moderator

Dr Soh Shui Yen, KK Women's and Children's Hospital, Singapore

Paediatric Approach to Cancer Predisposition

29 January 2022 | 09:00 AM - 10:30 AM

Heritable predisposition is an important cause of cancer in children and adolescents. Although many cancer predisposition genes and their associated syndromes and malignancies have already been described, it appears likely that there are more paediatric cancer patients in whom heritable cancer predisposition syndromes have yet to be recognized. This session summarized the current knowledge of cancer predisposition syndromes in paediatric oncology and provided essential information on clinical situations in which a childhood cancer predisposition syndrome should be suspected.



Panelists

Professor Xiaoli Ma, Beijing Children's Hospital, China

Dr Mei Jin, Beijing Children's Hospital, China

Dr Eric Fu, Hong Kong Children's Hospital, Hong Kong

Dr Wah Cheuk, Queen Elizabeth Hospital, Hong Kong

Convenors

Professor Godfrey Chan, Hong Kong Children's Hospital, Hong Kong

Dr Anthony Liu, Hong Kong Children's Hospital, Hong Kong

VIVA-Asia Rare Tumour Board Meetings #2

PEComa and differential diagnostic considerations

8 February 2021 | 6:00PM – 7:00PM

Two clinical vignettes were discussed by Professor Godfrey Chan and Dr Anthony Liu in a virtual tumour board meeting.

Professor Xiaoli Ma (Oncology), Dr Mei Jin (Oncology), and the pathology team from Beijing Children's Hospital shared their experiences with us on the management and therapy of a kid who had a rare spinal tumour.

Dr Eric Fu (Oncology, Hong Kong Children's Hospital) and Dr Wah Cheuk (Pathology, Queen Elizabeth Hospital), expert ophthalmologists and neurosurgeons with extensive experience in orbital tumours, shared their insights on the difficult diagnostic process and management on a patient with an orbital tumour.



15th St. Jude-VIVA Forum 2021

5 – 13 March 2021

The St. Jude-VIVA Forum in Paediatric Oncology (SJVF) is the combined effort between world leader St. Jude Children's Research Hospital (Memphis, Tennessee, USA) and the Singapore-based charity organisation VIVA Foundation for Children with Cancer. The SJVF provides paediatric oncologists in Asia the opportunity to learn and network with world and regional leaders, as well as to foster collaborations to save the lives of more children.



Self-Care Programme Webinar Series

Fundamentals of Self Care

18 April 2021 | 11:00AM – 12:00PM

Survivorship involves the transition from childhood adversity to life after treatment, a chapter that negotiates the attempt to form a connection between adaptation in this trajectory, engagement in life activities, late effects, uncertainty, and self-care strategies.

The consequences of adversity can last decades but they don't have to. By learning self-care skills, one will be able to manifest a regulatory physical, emotional, and behavioural mechanism that are essential in preventing the decline of one's wellbeing and promotes resilience to the challenges that confront.

The speaker gave a talk about self-care as an essential tool for self-regulation, and how to be empowered with self-care fundamentals and ways to bounce forward in times of challenge and crisis in this webinar.

Speaker

Ms Sasha Annabella Pereira, National University Hospital, Singapore

Moderator

Ms Laura Mei Lian Tan, National University Hospital, Singapore



Speaker

Ms Sasha Annabella Pereira, National University Hospital, Singapore

Moderator

Ms Laura Mei Lian Tan, National University Hospital, Singapore

Self-Care Programme Webinar Series

Morning Practice

24 May 2021 | 2:00PM – 3:00PM

Every morning is a special time of the day. The air is still and fresh, and the birds are chirping; all of nature is priming for a new day. Your nervous system is built to respond to the qualities of morning in the same way - ready for renewal. The more you tune into the energy of morning, the more it can help you set the tone for a better day. Start your day by developing a morning practice to keep you grounded, aligned and strong.

The speaker gave a presentation in which the audience learned about the science of a morning practice, the importance of cultivating your morning practice, and simple exercises to prime your wellbeing in the morning during this webinar.



Panelists

Dr Maribel Lacambra, The Chinese University of Hong Kong
 Dr Kevin Fung, Hong Kong Children's Hospital
 Dr Amanda Kan, Hong Kong Children's Hospital
 Dr Innes Wan, The Chinese University of Hong Kong
 Dr Max Lee, Kwong Wah Hospital, Hong Kong

Convenors

Professor Godfrey Chan, Hong Kong Children's Hospital, Hong Kong
 Dr Anthony Liu, Hong Kong Children's Hospital, Hong Kong

VIVA-Asia Rare Tumour Board Meetings #4

Huge thoracic tumour in a 9-year-old girl

25 May 2021 | 5:30PM – 6:30PM

In this webinar, the Hong Kong Team discussed a young girl with a huge thoracic tumour, focusing on the clinical features and management, diagnostic process and differential considerations, as well as a general discussion on working up patients with sarcomas.



Self-Care Programme Webinar Series

The magic of artificial eyes - why, when & how

30 June 2021 | 5:00PM – 6:00PM

Speakers

Dr Gangadhara Sundar, National University of Singapore, Singapore

Ms Suriya Abu Waled, National University Hospital, Singapore

Moderator

Ms Laura Mei Lian Tan, National University Hospital, Singapore

Ocular prosthesis, also known as Artificial Eyes, are prosthetic medical devices which are fabricated to replace and restore the appearance of a lost eye. Eyes in children and adults may be lost due to injuries or infections resulting in shrinkage (phthisis), from removal of eyes to save the life (cancers), the other eye (following irreparable injury) or rarely seen in children who are born without one or both eyes.

This presentation highlighted such unusual situations that are potentially medically, physically, and psychosocially devastating which once managed medically and/or surgically, are rehabilitated by a Custom-made ocular prosthesis by a Certified Ocular Prosthetician. The process of counselling, fabrication, fitting and maintenance will be presented in detail. Patient /family experiences are also shared in this session.

At the end of the presentation, the adult patients, their caregivers, and allied health professionals had better understanding of the various indications, processes and challenges in the fabrication and maintenance of ocular prosthesis.



Self-Care Programme Webinar Series

Real-life Caregivers stories- The Journey

21 July 2021 | 12:00PM – 1:00PM

Speaker

Rebecca Sit, Mother of an Acute Lymphoblastic Leukemia survivor

Moderator

Ms Laura Mei Lian Tan, National University Hospital, Singapore

To mark Childhood Cancer Awareness Month, we hosted a series of Childhood Cancer Awareness webinars in the months leading up to September. The first webinar focused on the experience of being a caregiver. To be told your child has cancer and watching him/her getting pricked and poked is gut-wrenching and devastating. Do you get emotional and cry at night? Were you on the internet and reading articles on everything relating to childhood cancer and lose sleep after? Sometimes when you see other healthy-looking children, do you feel sad and ask, "Why my child?". Do you get paranoid over the slightest of things related to your child then quickly call the ward to consult? Have you lost

your patience with your child after almost 30 minutes of coaxing him to take the medication? Rebecca felt all the above. Her role as a full-time caregiver to a critically sick child, to protect, to be familiar with the medical procedures, and to stay strong and positive amidst all this was not easy.

Every diagnosis and journey may be different, but through this series of Real-Life Caregiver Stories - The Journey, we hope Rebecca's sharing of her family's journey, her personal tips on self-care and ways to support a child with cancer will not only be useful, but also inspire fellow caregivers and families who are navigating their own childhood cancer journey.



VIVA-Asia Rare Tumour Board Meeting 5

Adrenocortical Carcinoma

30 July 2021 | 5:30PM – 6:30PM

VIVA Rare Tumour Board Webinar on Adrenocortical Carcinoma, presented by experts from Shanghai's Xinhua Hospital and Hong Kong's Children's Hospital.

Panelists

Prof Xiao-Jun Yuan, Xinhua Hospital, China
Dr Shi-Hao Huang, Xinhua Hospital, China
Prof Lili Liang, Xinhua Hospital, China
Prof Jin-ning Li, Xinhua Hospital, China
Dr Wen-bin Guan, Xinhua Hospital, China
Dr Jia Shi, Xinhua Hospital, China
Dr Carol Yan, Hong Kong Children's Hospital

Convenors

Professor Godfrey Chan, Hong Kong Children's Hospital, Hong Kong
Dr Anthony Liu, Hong Kong Children's Hospital, Hong Kong



Self-Care Programme Webinar Series

Real-life Caregivers stories- Parenting a child with cancer

18 Aug 2021 | 12:00PM – 1:00PM

Speaker

Rebecca Sit, Mother of an Acute Lymphoblastic Leukemia survivor

Moderator

Ms Laura Mei Lian Tan, National University Hospital, Singapore

We all want to be the best parents to our children, but when childhood cancer comes into the picture, it can become a major challenge for parents. Rebecca and her husband were the main sources of emotional support for their son, Damien, who was diagnosed with Leukaemia at 23 months old. While supporting him through treatment, how did they build a strong parent-child relationship while allowing him to continue

learning, growing, and enjoying childhood? Was the parenting journey lonely and how did they cope as parents without losing themselves? Join us in this next webinar as Rebecca shares her parenting journey and some fun activities you can do with your child during treatment.



Speaker
Rebecca Sit, Mother of an Acute Lymphoblastic Leukemia survivor

Moderator
Ms Laura Mei Lian Tan, National University Hospital, Singapore

Self-Care Programme Webinar Series

Real-life Caregivers stories- Childhood cancer - Living with, through it and life after
22 Sep 2021 | 12:00PM – 1:00PM

Seeing your child's end of treatment and surviving cancer brings mixed feelings of both joy and anxiety. From focusing on getting through their son's (Damien) treatment and beating the leukemia, to everyday life without continuous hospital contact as her safety net, then transiting off treatment and worrying about survivorship issues, Rebecca shares with us how her family adjusted to a "new normal" and is continuing to thrive and live life despite the worries they have after her son Damien achieved remission last year.



Speaker
Dr Bernice Oh, National University Hospital, Singapore

Moderator
A/Prof Alleh Yeoh, National University Hospital, Singapore

Self-Care Programme Webinar Series

CAR T cell therapy in Singapore: Practical considerations for patients and families
20 Oct 2021 | 5:00PM – 6:00PM

In patients with relapsed or difficult-to-treat acute lymphoblastic leukaemia, CAR T cell therapy is increasingly being used. The results of CART in these patients have been truly remarkable; patients are now cured with manageable side effects.

In this talk, we discussed the current landscape of CAR T cell therapy in Singapore and shared what is available here, including an overview of early results, potential costs involved and an introduction to newer therapies on the horizon. The speaker addressed common concerns so that families know what to expect before and after treatment and also discussed common side effects and how to prevent them.

This webinar sponsored with an educational grant by Novartis



Speaker
Prof Andre Baruchel, Hospital Saint-Louis, France


Moderator
A/Prof Alleh Yeoh, National University Hospital, Singapore

VIVA CAR-T Educational Webinar (HCPs)

CART- T Cells: The Future of Paediatric ALL
12 November 2021 | 5:00PM – 6:00PM

The marketing authorization of tisagenlecleucel, a 2nd generation of CD19-directed CAR T-cells, containing the 4-1 BB co-stimulatory domain, in 2017 in USA and in 2018 in EU, has revolutionized the therapeutic strategy in advanced B-cell acute lymphoblastic leukaemia (B-ALL) in children, adolescents and young adults (AYAs) with relapsed or refractory disease. This innovative treatment, based on a “living drug”, has shown very impressive short-term responses. However, safety profile and complex logistics require high expertise centres and tight collaborations between addressing and treating centres. Current research is exploring the possibility to move to first line ALL with high-risk features and/or first high-risk relapse. More efficient CAR T-cells products are still awaited to counteract the clonal escape mechanisms which have emerged. Moreover, to define the bridge-to-CAR for each patient remains a challenge to obtain optimal disease burden allowing expansion and persistence of CAR T-cells. Also difficult is to identify patients who will need a further therapy after infusion, such as allogeneic HSCT or may be immuno-modulatory treatment. Finally, CAR T-cells directed against T-ALL are only in their beginning but require a more complex engineering process to avoid T-cell immune-deficiency or fratricide. The future of this form of immunotherapy seems bright but the financial toxicity emerges as a major hurdle to equity in access for children an AYA with ALL.

This webinar sponsored with an educational grant by Novartis



VIVA-Asia Blood and Marrow Transplant School

VABMT Autumn School, Day 1
Infectious Complications in BMT
20 Nov 2021 | 2:00PM – 5:45PM


This VABMT Autumn School 2021 embarked on a new series of educational activities. This was based on the constructive feedback we have received in our recent schools. We had 2 afternoons of interactive talks focus on developing Paediatric HCT programs by using the FACT-JACIE standards as a guide to sequence the priorities with the aim to meet the learning needs of our global audience. We've put together two intriguing programs with renowned speakers who have a wealth of knowledge and expertise in their respective fields.

Speakers

Dr Chan Si Min, National University Hospital, Singapore, Prof Paul Anantharajah Tambyah, National University Hospital, Singapore
Dr Rie Aoyama, National University Children's Medical Institute, Singapore
Prof Cheng-Hsun Chiu, Chang Gung University College of Medicine, Taiwan

Organising Chairs

Assoc Prof Tan Poh Lin, National University Hospital, Singapore
Dr Frances Yeap, National University Hospital, Singapore



VIVA-Asia Blood and Marrow Transplant School

VABMT Autumn School, Day 2
Building a Paediatric BMT Program
21 Nov 2021 | 2:00PM – 5:45PM

This VABMT Autumn School 2021 embarked on a new series of educational activities. This was based on the constructive feedback we have received in our recent schools. We had 2 afternoons of interactive talks focus on developing Paediatric HCT programs by using the FACT-JACIE standards as a guide to sequence the priorities with the aim to meet the learning needs of our global audience. We've put together two intriguing programs with renowned speakers who have a wealth of knowledge and expertise in their respective fields.

Speakers

Dr Julia Palma Behnke, Calvo Mackenna Hospital, Chile
Dr Tan Lip Kun, National University Hospital, Singapore
Dr Lawrence Faulkner, Cure2Children Foundation, Florence-Italy

Organising Chairs

Assoc Prof Tan Poh Lin, National University Hospital, Singapore
Dr Frances Yeap, National University Hospital, Singapore



Speakers

Prof Wing Leung, The University of Hong Kong, Hong Kong
Dr Li Ben Shang, Shanghai Children's Medical Centre, China

Moderator

Prof Godfrey Chan, Hong Kong Children's Hospital, Hong Kong

VIVA CAR-T Educational Webinar


CAR-T therapy for ALL 急性淋巴细胞白血病的 CAR-T 细胞疗法

24 Nov 2021 | 5:00PM – 6:00PM

For parents, coping and caring for a child with acute lymphoblastic leukaemia (ALL) can be challenging, including the choice of treatments such as chemotherapy, radiation therapy, surgery, and bone marrow transplantation. Though these treatments are useful, they are not always successful and could result in many long-term side effects. Recently, chimeric antigen receptor modified T cells (CAR-T) become a new form of treatment for ALL. In this webinar, Dr Chan, Dr Leung, and Dr Li shared practical information with patients, survivors, their family members and caregivers on CAR-T Therapy and how it can save more children with ALL with less side effects.

应对和照顾患有急性淋巴细胞白血病（ALL）的孩子，对父母是一项艰巨的挑战，包括该选择化疗、放射治疗、手术还是骨髓移植等治疗方案？这些虽然是有效的治疗方案，但未必适用于每个病童，并且可能导致许多长期的副作用。嵌合抗原受体修饰 T 细胞（CAR-T）是近期治疗 ALL 的一种新方案。在本次网络研讨会上，梁医生、陈医生和李医生与患者、康复者、他们的家人和护理人员分享有关 CAR-T 治疗的实用信息，以及它如何能够以较少的副作用挽救更多患有 ALL 的儿童。

This webinar sponsored with an educational grant by Novartis



Panelists

Dr Rajkumar Venkatramani, Baylor College of Medicine, USA
Dr Amanda Kan, Hong Kong Children's Hospital
Dr Mario Li, Hong Kong Children's Hospital
Dr Cheuk Wah, Queen Elizabeth Hospital, Hong Kong

Convenors

Professor Godfrey Chan, Hong Kong Children's Hospital, Hong Kong
Dr Anthony Liu, Hong Kong Children's Hospital, Hong Kong


VIVA-Asia Rare Tumour Board Meeting #6

Paediatric Spindle Cell Rhabdomyosarcoma

15 Dec 2021 | 9:30PM – 10:30PM

In this meeting, the panellists had a discussion on spindle cell rhabdomyosarcoma. The Hong Kong team shared on the challenges in management for two patients, while Dr Raj Venkatramani, COG Soft Tissue Sarcoma Chair, enlightened us on the implications and treatment approach after diagnosing such rhabdomyosarcoma variant.


VIVA ACTIVITIES



In line with VIVA's mission of saving children with cancer lead healthier, happier and more productive lives, our Life Program is developed to help survivors in self-care, provide hope and skills through conducting programmes and activities to enhance and maintain physical as well as mental health and wellness.

ONLINE STORYTELLING

Due to COVID-19 restrictions, VIVA storytelling sessions were conducted online from October to December 2021. There were weekly sessions each of English session as well as Chinese session. For the English storytelling sessions, we had storytellers from all walks of life who volunteered, including Ms Selena Tan from Dimsum Dollies, Mrs Anne Mahbubani, and VIVA's Executive Chairman, Mrs Jennifer Yeo. For the Chinese storytelling sessions, we thank Hooks on Books who volunteered to do the storytelling. Many participants of all age group, local and overseas, joined in.



ORGANIC VEGETABLES

Starting in October 2021, Hemispheres Foundation provided sponsorship to VIVA by delivering to our beneficiaries complimentary organic vegetables once a month, as part of their Gift of Compassion project. Each month, 20 families will have a 5kg box of organic vegetables worth about \$50 delivered to their doorstep.



Reshvren, VIVA's beneficiary, in a photo here with the organic vegetables received

WOLFGANG CONCERT



Held on 16 & 17 Dec 2021 at the Victoria Concert Hall, the Wolfgang Violin Studio organized the Heart Strings concert, in support of VIVA Foundation for Children with Cancer.


It featured the Wolfgang Trailblazers, a concert by children for children, as well as Ms Min Lee, the Music Director.

Jay, our VIVA beneficiary, also participated in the performance. The concert was beautiful and inspiring. It raised more than \$20,000 for VIVA.

THANKSGIVING CONCERT (VIRTUAL)




To give thanks for all the blessings in life, VIVA Foundation put together an online concert for Thanksgiving on 25 Nov 2021 on Zoom. VIVA’s Executive Chairman gave a touching and inspiring message for this thanksgiving. Talented performers from all walks of life volunteered to perform in this hour long segment. About 200 participants from all over the world logged into the concert. Sr Rosalia Yeo sums it up: “Wonderful persons who light up our world with genuine care and love.”



CHRISTMAS CONCERT (VIRTUAL)



Due to the Covid-19 restrictions, VIVA’s Christmas concert was held online too. On 23 Dec 2021, the concert started off with a prayer for VIVA by Bishop Chong Chin Chung. A group of wonderful and talented volunteers, including a couple of VIVA’s directors and families, delighted the audience with a slew of Christmas songs, including The First Noel, Christmas Tree, Blue Christmas, to name a few. Wishing all a Merry Christmas and a Happy New Year!





VIVA FUNDRAISING

VIVA Hero Challenge 2021



This run was held from 4 April to 2 May 2021 and free for all to participate. It was a huge success, attracting nearly 3,000 participants. Participants clocked over 150km!



Over \$140,000 was raised for this event. VIVA thank all participants who made this run a meaningful one. Sincere thanks to the generous support and donations from our sponsors. With Toteboard's matching grant, over \$240,000 was raised.



VIVA-Jumbo Seafood Shioh Feast



As a supporter of VIVA Foundation, Mr Ang Kiam Meng, Executive Director and Group CEO of Jumbo Group, is inspired by the strength and perseverance of children who are battling cancer. He hopes to aid the needs and facilitate support for these children and the foundation to ensure they will have the same opportunities to live and fully recover to live out the full potential of their lives. VIVA thanks Mr Ang for donating 50 tables for our fundraising.



VIVA-JUMBO SEAFOOD SHIOH FEAST 2021
MENU - OPTION 1

BRAISED FISH MAU SOUP WITH DRIED SCALLOP CRAB MEAT AND SEA CUCUMBER
This traditional delicacy is served in a specially brewed chicken bone and shiitake mushroom broth, to uplift the significant texture of the Braised scallop and the succulence of the crab meat.

DEEP FRIED LIVE SOON HOCK WITH OYSTER SAUCE
Live Marble Goby boasts of juicy, white flesh rich in albumin protein, skillfully deep fried with just a dash of oyster sauce to preserve its sweet, delicate taste and the natural succulence of the meat.

10 HEAD ABALONE BRAISED WITH SHIITAKE MUSHROOM AND BROCCOLI
Known as "the emperor of seashells", this highly-priced ingredient from the waters of Australia, the 5-headed Abalone is braised in premium oyster sauce and served with highly valued Shiitake Mushrooms known as Flower Mushrooms, distinct for its flower pattern on its cap and fragrance. Typically reserved for special occasions like Chinese New Year, fans of abalone and mushroom will be delighted by this exquisite interpretation of these nutrient-rich delicacies.

MOCHA PORK RIBS
The finest selection of premium pork ribs the scored to perfection, and tossed with homemade specialty coffee rub. A jerk tender, melt in your mouth experience, filled deep and rich flavor bound to create a sensational experience on your palette.

JUMBO AWARD-WINNING CHILLI CRAB WITH FRIED MINI BUNS
Live crabs drowned in a mouth-watering sauce expertly fused by our chefs with a myriad of over 30 different Southeast Asian spices, this flavorful blend of spiciness tinged with a sweet sourness enfolds a subtle eggy fragrance that brings out the freshness of crab. Featuring ingredients that straddle different races and cultures, this is one dish that epitomizes the multi-faceted culinary culture that is uniquely Singapore.

SUPREME SEAFOOD FRIED RICE
JUMBO Seafood brings you nothing but a composition of the highest quality seafood ingredients, sweetened counterbalanced against the fragrance of "wok hei" - a complex charred aroma achieved only by the most skillful of chefs.

CHILLED MANGO SAGO POMELO
Finish off with one of the best classic dessert done right. Fresh Mango paired with smooth creamy texture, topped with Sago and Pomeelo.

Sponsored By: **JUMBO SEAFOOD**

VIVA-JUMBO SEAFOOD SHIOH FEAST 2021
MENU - OPTION 2

ROYALE SEAFOOD PACK FOR 5
Live Mud Crab (1800g - 2000g), Live Boston Lobster (1500g), Nine Long Nix (200g), Clams (200g), Mussel (200g), Prawns (400g), Pearl Cams (200g)

CHOICE OF SAUCE (PLEASE CHOOSE 2)
Sauce: Nanya Sauce, Chili Crab Sauce, Black Pepper Sauce, or Creamy Butter Sauce
(Note: Seafood will be split into 2 bags)

HACK IT SIGNATURE SALAD
Hack It Signature Mixed greens with avocado, rock melon, star fruit, cherry tomatoes, and crunchy 'chai pok' bits, drizzled with homemade yuzu sauce and crushed peanuts

MIXED FRUIT SALAD WITH SESAME DRESSING
Mixed greens with fresh avocado, rock melon, starfruit and cherry tomatoes, drizzled with fragrant sesame sauce

SEAFOOD BACON ROLL
Fresh seafood paste wrapped in savory bacon strips and layered with a dollop of cold cream for perfect sweet ending.

HACK IT MID WINGS
Crispy mid wings coated with HACK IT sweet and sour sauce

SEAFOOD BAKED RICE WITH CHILI CRAB SAUCE
Aromatic fried rice baked with seafood, mozzarella cheese and tangy signature Chili crab sauce

GARLIC FRIED RICE
Fragrant Jasmine white rice wok-fried with crispy garlic and spring onions.

DEEP-FRIED MAN TOU (12 PIECES)
Mini 'Man-Tou' deep-fried till golden brown

Sponsored By: **JUMBO SEAFOOD**

VIVA-JUMBO SEAFOOD SHIOH FEAST 2021
MENU - OPTION 3

THAI STYLE SHARKS' FIN SOUP BRAISED WITH CRAB MEAT
This traditional delicacy is served in a specially brewed chicken bone and shiitake mushroom broth, to uplift the significant texture of the Shark's Fin and the succulence of the crab meat.

DEEP FRIED LIVE SOON HOCK WITH OYSTER SAUCE
Live Marble Goby boasts of juicy, white flesh rich in albumin protein, skillfully deep fried with just a dash of oyster sauce to preserve its sweet, delicate taste and the natural succulence of the meat.

5 HEAD ABALONE BRAISED WITH SHIITAKE MUSHROOM AND BROCCOLI
Known as "the emperor of seashells", this highly-priced ingredient from the waters of Australia, the 5-headed Abalone is braised in premium oyster sauce and served with highly valued Shiitake Mushrooms known as Flower Mushrooms, distinct for its flower pattern on its cap and fragrance. Typically reserved for special occasions like Chinese New Year, fans of abalone and mushroom will be delighted by this exquisite interpretation of these nutrient-rich delicacies.

LIVE BOSTON LOBSTER STEAMED WITH MINCED GARLIC AND GLASS VERMICELLI
Boasting on a bed of delightfully springy vermicelli glass noodles, enjoy juicy, succulent lobster meat

JUMBO AWARD-WINNING CHILLI CRAB WITH FRIED MINI BUNS
Live crabs drowned in a mouth-watering sauce expertly fused by our chefs with a myriad of over 30 different Southeast Asian spices, this flavorful blend of spiciness tinged with a sweet sourness enfolds a subtle eggy fragrance that brings out the freshness of crab. Featuring ingredients that straddle different races and cultures, this is one dish that epitomizes the multi-faceted culinary culture that is uniquely Singapore.

SUPREME SEAFOOD FRIED RICE
JUMBO Seafood brings you nothing but a composition of the highest quality seafood ingredients, sweetened counterbalanced against the fragrance of "wok hei" - a complex charred aroma achieved only by the most skillful of chefs.

Sponsored By: **JUMBO SEAFOOD**

We thank all donors for supporting VIVA in this fundraising effort. As we wrapped up the event, the funds raised exceeded \$600,000 with matching grant from Toteboard. VIVA will work hard to achieve our mission to support our beneficiaries.

<<Love.Hope>> VIVA Foundation – Aspiration Fine Arts Charity Art Exhibition

(17 – 21 NOV 2021, 11AM-6.30PM/ OPENING CEREMONY ON 16 NOV 2021, 6PM) at ION Art Gallery



This Charity Art Exhibition is of special significance. It is the first time that VIVA Foundation for Children with Cancer (VIVA Foundation) and Aspiration Fine Arts (Aspiration) are jointly organising this Art Exhibition to raise donations for VIVA's Life Programme. VIVA Foundation and Aspiration have worked very hard to make this exhibition memorable and meaningful. We hope to deliver the message of love and hope, through art, especially to children with cancer. Hence, <<LOVE.HOPE>>.

Nearly 200 members from Aspiration enthusiastically responded to donate their personal art works to be presented as gifts of appreciation to donors. We thank Mr Lin LuZai, founder of Aspiration Fine Arts, and his students who worked so hard to help support VIVA's mission to help the children with cancer.

We were also extremely honoured that Mrs Josephine Teo, Minister for Communication & Information and Second Minister for Home Affairs officiated the opening of this charity exhibition on 16th Nov 2021. We thank ION Turn Pte Ltd for sponsoring the beautiful venue at ION@Art Gallery and Mrs Peggy Loh and her students for enhancing the exhibition hall with 11 amazing pieces of Ikebana arrangements.

We raised more than \$370,000, thanks to all the artists and donors! With support of the matching grant from Toteboard, nearly \$500,000 was raised.





‘富贵平安 事事顺心’ - 林禄在老师



‘富贵满堂’ - 林禄在老师

Some paintings donated by Mr Lin LuZai, founder of Aspiration Fine Arts and Mrs Cynthia Lee, Director of VIVA



‘鸟儿的喜悦’ - 潘惜玉女士



‘森林之星’ - 潘惜玉女士

Business China Awards 2021



The Business China Excellence Award is awarded to one who can best demonstrate exceptional vision and leadership in the development and sustained growth of a business or profession in Singapore or China, respectively. He/she must also be an exemplary role model to other Singaporeans in the learning and appreciation of the Chinese language and culture.

It is with pride that we congratulate our Executive Chairman (pro bono), Mrs Jennifer Yeo, on being the winner of this prestigious award.





Cancer does not stop, even in the midst of the Covid-19 pandemic. It has made things even harder for kids with cancer. With compromised immunities, they have had to stay home since the beginning of the outbreak -- unable to go to school, meet friends and go outside due to heightened risks from childhood cancer. It is even more important for them to stay home and practice social distancing.

As a response to the pandemic, VIVA conducted online programmes with the support of partners and volunteers. Other than VIVA's online education webinars, there was VIVA's online storytelling sessions that were conducted via Zoom twice weekly, English and Mandarin, from October to December 2021. These were attended by children and adults alike, and attended by international participants from Myanmar and Indonesia! Other examples, are our well-attended online Thanksgiving as well as Christmas concerts.

VIVA wishes to thank partners, supporters, donors and sponsors for enabling us to implement online VIVA programmes during the Covid-19 pandemic. VIVA also thank all participants for joining our programmes.

VIVA IN THE PRESS



- Association of Genetic Ancestry with the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia ([JAMA Oncology, January 27, 2022](#))
- Helping our neighbours in the war against childhood brain and solid tumours, one fellow at a time (SingHealth, 20 Oct 2020)
- Brain and Solid Tumours Amongst Children, Interview with Dr Amos Loh (Health Matters, CNA 938, August 2020)
- Covid-19 heroes: Activity kits bring joy to kids in need (The Straits Times, Aug 2020)
- Ching-Hon Pui, MD, receives Medal of Honor from the American Cancer Society (EurekAlert, March 2020)
- Partnership with China Prompts Change in Care for High-Risk Type of Leukemia (Newsweek, Jan 2020)
- British boy who came to Singapore for treatment for aggressive cancer is 'almost ready to go home' (The Straits Times, 17 Jun 2020)
- British boy, 5, in Singapore for experimental treatment for 'uncontrollable' cancer (The Straits Times, 5 Jan 2020)
- NUS Medicine researcher wins Gabbay award for CAR-T Immunotherapy (BioSpectrum, 1 Aug 2019)
- Cellular therapy gives hope to cancer patients (The Straits Times, 1 Aug 2019)
- Patients resistant to chemotherapy found to respond to immunotherapy; trials to begin in January (The Straits Times, 31 July 2019)
- Gabbay award given to scientists whose research brought about new cancer treatments (Brandeis University, 22 May 2019)

..

STATEMENT OF FINANCIAL ACTIVITIES

For the Financial Year Ended 31 December 2021

INCOME

	2021 S\$	2020 S\$
Unrestricted General Funds		
Income from generated funds		
- Voluntary income	717,573	1,908,983
- Investment Income	23,444	46,153
- Activities for generating funds	1,099,137	2,600
Income from charitable activities	86,352	273
Other Income	46,678	61,529
TOTAL INCOME	1,973,184	2,019,538

EXPENDITURES

Cost of generating funds		
- Cost of generating voluntary income	17	32,588
- Cost of activities for generating funds	19,997	-
Charitable activities	215,778	1,329,072
Governance costs	1,108,297	918,969
TOTAL EXPENDITURES	1,344,089	2,280,629

Net income (expenditure)/income before tax expense	629,095	(261,091)
---	---------	-----------

Tax expense	-	-
--------------------	---	---

Net (income) expenditure	629,095	(261,091)
---------------------------------	---------	-----------

Gross transfers between funds	-	-
-------------------------------	---	---

Net movement in funds	629,095	(261,091)
------------------------------	---------	-----------

Reconciliation of funds

Total funds brought forward	25,361,172	25,622,263
Total funds carried forward ^(A)	25,990,267	25,361,172

Excerpted from the full Audited Financial Report 1 Jan 2021 to 31 Dec 2021, which will be attached separately to this Annual Report.

STATEMENT OF FINANCIAL POSITION

For the Financial Year as at 31 December 2021

	2021 S\$	2020 S\$
Non-Current Assets		
Property and Equipment	18,972,029	19,447,432
Current Assets		
Inventories	2,414	2,264
Other receivables and prepayments	417,566	237,932
Cash and cash equivalents	6,683,989	5,772,650
	7,103,969	6,012,846
Current Liabilities		
Accrued Expenses	13,188	566
Deposits Received	15,843	50,014
Other payables	56,700	48,526
	85,731	99,106
Net Current Assets	7,018,238	5,913,740
Total Assets Less Current Liabilities	25,990,267	25,361,172
Funds of Charity		
<u>Unrestricted Funds</u>		
General funds	25,990,267	25,361,172
TOTAL CHARITY FUNDS	25,990,267	25,361,172

STATEMENT OF CASH FLOW

For the Financial Year Ended 31 December 2021

	2021 S\$	2020 S\$
Cash Flows from Operating Activities		
- Net income/(expenditure) before tax expense	629,095	(261,091)
Adjustments for:		
- Depreciation of property and equipment	524,096	528,749
- Interest income	(23,444)	(46,153)
Operating cash flows before changes in working capital	1,129,747	221,505
- Other receivables and prepayments	(179,634)	(80,093)
- Inventories	(150)	(2,264)
- Accrued expenses	12,622	(6,259)
- Other payables	8,174	1,228
- Deposits received	(34,171)	-
Net cash flows generated from / (used in) operating activities	936,588	134,117
Cash Flows from Investing Activities		
- Purchase of equipment	(48,693)	(2,119)
- Increase in short-term deposits with maturity over 3 months	(22,750)	(952,500)
- Interest received	23,444	46,153
Net cash flows generated from investing activities	(47,999)	(908,466)
Net increase/(decrease) in cash and cash equivalents	888,589	(774,349)
Cash and cash equivalents at the beginning of the year	2,272,650	3,046,999

COMMUNITY PARTNERSHIP

(Other Charity Funds)

The charity held donation drives to raise funds for specific projects. As at 31 December 2021, a total fund of S\$82,276,017 (2020:S\$80,273,867) was raised by the Charity with a government matching grant of S\$46,200,037 (2020: S\$45,066,578)

The details of the funds are divided into three categories as follows:

- (A) specific donations received under the Charity as donation income;
- (B) specific donations co-funded by the Charity and Community Partners; and
- (C) specific donations paid directly to the Community Partners as beneficiaries.

Except as disclosed in Note 14, the details of funds which the donations and the amounts expended below are not reflected in the financial statements of the Charity.

	Cumulative Funds raised as at 31 December 2021		Fund Balances as at 31 December 2021	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
(A) Specific donations received under the Charity as donation income				
Donated space (Note 14)	24,100,000	-	18,918,500	-
Available fund balance (Note 14)	11,771,500	-	7,071,767	-
VIVA-NUS CentRAL (Note 17 A1)	8,026,692	-	1,793	-
VIVA-Mr Goh Hup Jin Fund (Note 17 A2)	1,300,174	-	1,071,077	-
Cancer Immunotherapy (Note 17 A3)	1,000,000	-	-	-
Subtotal	46,198,366	-	27,063,137	-
(B) Specific donations co-funded by the Charity and Community Partners				
VIVA-KKH Childhood Brain and Solid Cancers Programme (Note 17 B1)	13,257,349	12,951,588	4,133,218	12,950,000
(C) Specific donations paid directly to the Community Partners as beneficiaries				
NUS Children Cancer Centre Fund (Note 17 C1)	2,490,318	4,219,031	1,430,143	2,502,913
NUH Health Research Endowment Fund (Note 17 C2)	7,264,020	3,205,984	-	5,527,199
VIVA Paediatric Oncology Fund (Note 17 C3)	12,285,964	24,496,574	544,459	13,821,883
VIVA Education and Research Fund (Note 17 C4)	780,000	1,326,860	-	768,593
Subtotal	22,820,302	33,248,449	1,974,602	22,620,588
Total	82,276,017	46,200,037	33,170,957	35,570,588

*For Notes, reference is made to Audit Report

COMMUNITY PARTNERSHIP

(Other Charity Funds)

	Cumulative Funds raised as at 31 December 2020		Fund Balances as at 31 December 2020	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
(A) Specific donations received under the Charity as donation income				
Donated space (Note 14)	24,100,000	-	19,400,500	-
Available fund balance (Note 14)	9,798,490	-	5,960,672	-
VIVA-NUS CenTRAL (Note 17 A1)	8,026,692	-	1,793	-
VIVA-Mr Goh Hup Jin Fund (Note 17 A2)	1,300,000	-	1,300,000	-
Cancer Immunotherapy (Note 17 A3)	1,000,000	-	-	-
Subtotal	44,225,182	-	26,662,965	-
(B) Specific donations co-funded by the Charity and Community Partners				
VIVA-KKH Childhood Brain and Solid Cancers Programme (Note 17 B1)	13,257,349	12,951,588	5,017,997	12,950,000
(C) Specific donations paid directly to the Community Partners as beneficiaries				
NUS Children Cancer Centre Fund (Note 17 C1)	2,488,622	4,084,512	1,475,950	2,530,639
NUH Health Research Endowment Fund (Note 17 C2)	7,237,009	3,000,000	2,294,228	3,000,000
VIVA Paediatric Oncology Fund (Note 17 C3)	12,285,705	23,743,824	1,343,039	13,719,636
VIVA Education and Research Fund (Note 17 C4)	780,000	1,286,654	-	776,215
Subtotal	22,791,336	32,114,990	5,113,217	20,026,490
Total	80,273,867	45,066,578	36,794,179	32,976,490

*For Notes, reference is made to Audit Report

(A) Specific Donations Received under the Charity as Donation Income

The Charity received donations for certain designated funds. These donations were reflected in the financial statements of the Charity as donation income. Subsequently, the Charity donated these to the designated fund managed by the Community Partners. The donated amounts were reflected in the financial statements of the Charity as expenditure incurred for charitable activities. The details of the funds which the amounts expended are not reflected in the financial statements of the Charity are as follows:

(A1) VIVA-NUS Centre for Translational Research in Acute Leukaemia (“CentRAL”)

	2021		2020	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	1,793	-	(217,610)	-
- Add/(Less):				
- Donation received	-	-	-	-
- Other income	-	-	254,593	-
- Expenditures	-	-	(35,190)	-
Balance at 31 December	1,793	-	1,793	-
Total Funds Raised by the Charity	8,026,692	-	8,026,692	-

The funds were donated by the Charity to the National University of Singapore to support the advancement of education and research with the establishment of CentRAL, a state-of-the-art leukaemia research and diagnostic facility with the key objective of improving the cure rates and quality of life of patients with leukaemia and haematologic cancer in Singapore and the Asia region, through accurate leukaemia classification, prediction and determination of treatment response.

(A2) VIVA-Mr Goh Hup Jin Fund for Translational Research in Acute Leukaemia (“CentRAL”)

	2021		2020	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	1,300,000	-	-	-
- Add/(Less):				
- Donation received	-	-	1,300,000	-
- Other income	174			
- Expenditure	(229,097)			
Balance at 31 December	1,071,077	-	1,300,000	-
Total Funds Raised by the Charity	1,300,000	-	1,300,000	-

The funds were donated by Mr Goh Hup Jin to support the advancement of education and research at CentRAL. As at 31 December 2020, these amounts have been subsequently donated by the Charity to CentRAL.

(A3) Cancer Immunotherapy

	2021		2020	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	-	-	-	-
- Less:				
- Expenditures	-	-	-	-
Balance at 31 December	-	-	-	-
Total Funds Raised by the Charity	1,000,000	-	1,000,000	-

The funds were donated by the Charity to Yong Loo Lin School of Medicine, National University of Singapore, to fund cancer immunotherapy clinical research, specifically to support clinical trials of novel therapies based on immune cells for children and adults with drug resistant cancer. During 2014, a S\$1 million donation was made to NUS by the Charity.

(B) Specific Donations Co-funded by the Charity and Community Partners

The Charity and Community Partners raised funds separately where the contributions by donors were designated for specific purposes. The Charity donations were reflected in the financial statements of the Charity as donation income. Subsequently, when the Charity donated these to the designated funds managed by the Community Partners, the amounts were reflected in the financial statements of the Charity as an expenditure incurred for charitable activities. The details of the funds which the amounts expended were not reflected in the financial statements of the Charity are as follows:

(B1) VIVA-KKH Childhood Brain and Solid Cancers Programme

	2021		2020	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	5,017,997	12,950,000	5,312,631	12,951,588
<u>Add/(Less):</u>				
- Expenditures	(884,779)	-	(294,634)	(1,588)
Balance at 31 December	4,133,218	12,950,000	5,017,997	12,950,000
Total Funds Raised by the Charity	13,257,349	12,951,588	13,257,349	12,951,588

The funds were donated by the Charity to KKH Health Fund (formerly known as KKH Health Endowment Fund) used for the advancement of the treatment and cure for children with brain and solid tumours in Singapore and the Asia Pacific region under the VIVA-KKH Childhood Brain and Solid Cancers Programme. This programme focuses on four areas of childhood brain and solid cancers in clinical care, translational research, registry-based population science, and collaborative education and training. During the previous financial year ended 31 December 2019, a S\$2 million donation was made to VIVA-KKH by the Charity.

(C) Specific Donations Paid Directly to Community Partners as Beneficiaries

The Charity raised funds for the following four projects, where the contributions by donors were designated for specific purposes and paid directly to the Community Partners. The details of the funds which the donations and the amounts expended below are not reflected in the financial statements of the Charity are as follows:

(C1) NUS Children Cancer Centre Fund (“CCCCF”)

	2021		2020	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	1,475,950	2,530,639	1,645,106	3,959,542
<u>Add/(Less):</u>				
- Investment income	1,636	134,519	17,682	-
- Other income	60	-	3,109	-
- Expenditure	(47,503)	(159,939)	(189,947)	(168,793)
- Investment loss		-		(91,542)
- Transfer to unrestricted endowment		-		(571,110)
- Transfer to unrestricted non-endowment fund		(2,306)		(597,458)
Balance at 31 December	1,430,143	2,502,913	1,475,950	2,530,639
Total Funds Raised by the Charity	2,490,318	4,219,031	2,488,622	4,084,512

The funds were donated to the National University of Singapore – Children Cancer Centre Fund to establish a children’s cancer centre, now known as the VIVA-University Children’s Cancer Centre (“VUC3”) at the National University Hospital which will be the centre of excellence for the treatment and cure of childhood cancer particularly leukaemia; the training and hiring of doctors, nurses, technical and administrative personnel from Singapore and the region; clinical and translational research; cellular therapy and stem cell transplantation. The funding is by VIVA Foundation and by Singapore Totalisator Board.

(C2) NUH Health Research Endowment Fund (“HREF”)

	2021		2020	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	2,294,228	3,000,000	2,250,257	3,000,000
<u>Add/(Less):</u>				
- Other income	27,011	5,984	43,995	-
- Donation received		200,000		
- Expenditure	(6)	(18)	(24)	-
- Transfer to unrestricted endowment fund	(2,321,323)	2,321,233		
Balance at 31 December	-	5,527,199	2,294,228	3,000,000
Total Funds Raised by the Charity	7,624,020	3,205,984	7,237,009	3,000,000

The funds were donated to the National University Hospital to establish the Mrs Lee Kong Chian Memorial Chair, for Director of Advanced Clinical and Translational Research for Childhood Leukaemia and Cellular Therapy under the VIVA Children's Cancer Programme. The donation of S\$3 million was received from the Lee Foundation, via the VIVA Foundation and was matched by the Ministry of Health with S\$3 million in two payments received on December 2006 and March 2007. The money was used as a bridging loan to support the setting up of the VIVA University Children's Cancer Centre.

(C3) VIVA Paediatric Oncology Fund ("VPOF")

	2021		2020	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	1,343,039	13,719,636	2,275,146	22,146,568
<u>Add/(Less):</u>				
- Investment income	-	752,750	15,512	-
- Other income	259	-	-	-
- Expenditure	(798,839)	(609,915)	(947,619)	(953,505)
- Investment Loss	-	-	-	(498,820)
- Transfer to unrestricted endowment fund	-	-	-	(3,396,110)
- Transfer to unrestricted non-endowment fund	-	(40,588)	-	(3,578,497)
Balance at 31 December	544,459	13,821,883	1,343,039	13,719,636
Total Funds Raised by the Charity	12,285,964	24,496,574	12,285,705	23,743,824

The VIVA Paediatric Oncology Fund has been established with an expendable gift of S\$12 million dollars from the Goh Foundation with a matching grant from the Singapore Government to Yong Loo Lin School of Medicine, NUS. The fund is used to advance paediatric oncology including, but not limited to, supporting the VIVA University Children's Cancer Centre and St. Jude VIVA Children's cancer programme. This programme aims to expand the services in paediatric oncology at the National University Health System and to establish for strategic research programmes in the following fields: 1) Bone Marrow Transplant, 2) Childhood Leukaemia, 3) Bone Cancer, 4) After-Completion-of-Therapy and to set up a professorship in paediatric oncology.

(C4) VIVA Education and Research Fund (“VERF”)

	2021		2020	
	Donations Received S\$	Government Matching Grant S\$	Donations Received S\$	Government Matching Grant S\$
Balance at 1 January	-	776,215	-	1,130,543
<u>Add/(Less):</u>				
- Investment income	-	-	-	-
- Investment loss	-	(47,703)		(26,240)
- Transfer to unrestricted endowment fund	-	-		(160,720)
- Transfer to unrestrict- ed non-endowment fund	-	(125)	--	(167,368))
Balance at 31 December	-	768,593	-	776,215
Total Funds Raised by the Charity	780,000	1,326,860	780,000	1,286,654

The funds were donated by the Charity to the National University of Singapore, Department of Paediatrics in support of education, training and research in paediatric oncology specifically through projects that are part of the VIVA Children’s Cancer Programme and income and expenses for the Annual St. Jude VIVA Forum in paediatric oncology. In 2013, the fund was closed and the balance of S\$78,448 was refunded to the Charity.

CODE OF GOVERNANCE

COMPLIANCE WITH CODE OF GOVERNANCE

VIVA Foundation constantly works towards compliance with the Charities Act, Charities (Institutions of Public Character) Regulations, Charities Accounting Standards, the Code of Governance for Charities and IPCs and the Personal Data Protection Act, and take steps to address and resolve weakness/es where appropriate.

MANAGING CONFLICT OF INTEREST

VIVA Foundation has in place a policy relating to the management and avoidance of conflict of interests. All Members, Directors and staff are required to sign the prescribed Declaration of Conflict of Interest form when they are appointed and thereafter annually or whenever there is any material change in the information contained in their respective Declarations.

ONLINE GOVERNANCE EVALUATION CHECKLIST (GEC) via CHARITY PORTAL

VIVA Foundation has been submitting the GEC annually via the Charity Portal. These are also available on VIVA's website at www.viva.sg.

RESERVES POLICY

VIVA Foundation has set aside a reserve of \$1 million to provide financial stability and resources for the development of its principal activities. The Board will periodically review the amount of reserves that are required to ensure adequacy in fulfilling the Foundation's obligations.

SALARIES AND RELATED COSTS

No Directors received any remuneration. During the financial year 2018, no staff personnel received an annual remuneration of \$100,000.00 and above. No staff is involved in setting his/her own remuneration.

VIVA discloses that there is no paid staff, being a close member of the family belonging to the Executive Head or a governing board member of the charity, who has received remuneration exceeding \$50,000 during the financial year.

REELECTION OF DIRECTORS

Board of Directors appointed during the financial year were re-elected by the Members at the Annual General Meeting.

VIVA Foundation does not have term limits of Directors/Members as the Board believes that continued contribution by each Director provides benefits to the foundation. Each Director's integrity is not compromised by the long period of service.

The Board decided, with the Members' approval, that Directors who serve in the Board for more than 10 years are retained. All Directors who are over the age of 70 years were re-appointed to hold office until the conclusion of the next Annual General Meeting of the Company pursuant to Section 153(6) of the Companies Act, Chapter 50.

BOARD MEMBERS ATTENDANCE AT MEETINGS

During the year, five (5) meetings were held – 3 Ordinary Board Meetings, 1 Finance Committee Meeting and 1 Annual General Meeting. Director(s) who is/are unable to attend any meeting in person may participate via teleconference.

The Board is satisfied that each Director is committed towards fulfilling the mission of VIVA Foundation. This is evidenced by their respective valuable contributions in many ways despite not attending some or all of the meetings during the year due to prior commitments.

INTERNAL CONTROL AND RISK MANAGEMENT MEASURES

The Board assumes overall responsibility and is fully committed on maintaining a sound system of internal control and risk management that provide reasonable assurance of effective operations and statutory compliance in accordance with the Code of Governance and Charity Accounting Standards.

The Board ensures that there is a sound internal control policies and procedures in place.

The Board constantly reviews, taking into account changes in the regulatory and statutory, these policies and procedures to ensure adequacy and effectiveness.

The Board has also put in place a risk management policy. One of these policies is the implementation of internal controls as part of the day to day operations.

VOLUNTEER MANAGEMENT

VIVA discloses that there are volunteer management processes in place for volunteers.

BOARD OF DIRECTORS

In 2020, two (2) Ordinary Board Meetings and one (1) Annual General Meeting were held. The Executive Committee* actively oversees the business of VIVA. The VIVA Board of Directors, comprising 12 Directors, serves pro-bono and ensures that VIVA's mission and vision are met.

EXECUTIVE COMMITTEE



Mrs Jennifer Yeo
(Mdm Leong Lai Peng)
Founder and Chairman

Senior Consultant, RHTLaw
Advocate & Solicitor, Singapore
Solicitor, England & Wales

Appointed on 6 Feb 2006



Mdm Kuok Oon Kwong
Vice-Chair

Chairman, National Healthcare
Group
Director, Shangri-La Hotel Ltd
Singapore

Appointed on 9 Nov 2007



Mr Christopher Wilson
Co-Founder, Water and
Healthcare Foundation

Appointed on 15 Jan 2015



Ms Shulamite N K Khoo
Independent Director,
CIMB Group

Appointed on 1 May 2018



Ms Cynthia Phua
Management Consultant
Former Singapore Member of
Parliament (2001-2011)

Appointed on 17 Jun 2019

BOARD OF DIRECTORS

BOARD OF DIRECTORS



Ms Tan Bee Lan
President,
Columbia China

Appointed on 1 Aug 2014



Mr Martino Tan
Managing Editor,
Mothership.sg

Appointed on 1 May 2018



Mdm Yeong Yoon Ying
Director (Special Duties),
Ministry of Communications
and Information

Appointed on 18 Jan 2019



Ms Djaan-Yi Lin
Senior Partner,
McKinsey Singapore

Appointed on 7 Apr 2020



Mr Tham Sai Choy
Chartered Accountant

Appointed on 1 Jan 2021



Mr K K Chua
Vice Chairman,
Mary Kay Inc

Appointed on 1 Jan 2021

EXTERNAL ADVISORY BOARD

VIVA's External Advisory Board (EAB) is made up of an international panel of renowned doctors from the global field of cancer care and research. The VIVA Board of Directors seeks strategic advice and views from the EAB with regards to programmes and projects.

The EAB meets in Singapore once a year. At other times of the year, the Board would also call on the EAB for their expert views and thoughts when necessary.



Dr. Ching-Hon Pui, MD
Chairman

American Cancer Society Professor
Chair, Department of Oncology
Co-Leader, Hematological
Malignancies Program
Fahad Nassar Al-Rashid Chair of
Leukemia Research
Director, China Region,
St. Jude Global, St. Jude Children's
Research Hospital
Memphis, Tennessee, USA

Appointed on 19 Dec 2006



Dr Rupert Handgretinger, MD
Member

Professor and Chairman,
Department of General Paediatrics
and Hematology / Oncology
Children's University Hospital
Tuebingen, GERMANY

Appointed on 7 Dec 2006



Dr Edward Holmes, MD
Member

President and CEO, Sanford
Consortium for Regenerative
Medicine
Senior Fellow, A*STAR Advisor
National Research Foundation
SINGAPORE

Appointed on 30 Nov 2006



Prof Anjo Veerman, MD
Member

Professor Emeritus, Paediatrics
Vrije Universiteit University
Medical Center
Amsterdam, THE NETHERLANDS

Appointed on 18 Dec 2006



Prof Wing Leung, MBBS, PhD
Member

Director and Senior Consultant,
Paediatric Bone Marrow Transplant
and Cell Therapy Centre
Senior Consultant, Haematology
Oncology Service, KK Women's and
Children's Hospital
Professor, Duke-NUS Medical
School
Chair, TCL-CCF Professorship
SINGAPORE

Appointed on 25 Feb 2020



TO A HOLISTIC FUTURE FOR SURVIVORS

Since VIVA began in 2006, we have been working towards our mission to save more lives for children with cancer through excellence in research, medical care, and education—embarking on impactful collaborations and exchanges that have paid dividends in improving survival rates for childhood cancer patients.

While our work in these areas continue, VIVA is also taking a holistic approach towards cancer care by introducing programmes that focus on the physical, mental, and emotional health and well-being of patients and survivors.

We will be launching the VIVA Life Programme, which will bring together collaborators to provide holistic survivorship care for those affected by childhood cancers. It is our belief that care does not end upon discharge from treatment centres, but rather, children and families affected by childhood cancer continue to need care and support in order to enable the child to not just survive, but thrive.

With love,

VIVA Foundation for Children with Cancer



Thank You!

VIVA would like to express our warmest gratitude to all our donors, volunteers and supporters who contributed to our mission in 2021.

We could not have done this without you.



bit.ly/donate2viva

Help us rewrite the future of kids with cancer.

Donate to the **VIVA Foundation**
for Children with Cancer today.

bit.ly/donate2viva



Scan the QR code
with your preferred
banking app to
donate instantly!

Connect with Us

8 Sinaran Drive
#03-01 Novena Specialist Centre
Singapore 307470

☎ 6221 2221
✉ enquiry@viva.sg

www.viva.sg



@VivaFoundation